MUKILTEO, Wash., June 16, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that Dr. Mansoor Mohammed, President and CEO of its laboratory service subsidiary, CombiMatrix Diagnostics, will present one of four keynote speeches at the 2010 World Cancer Congress on June 22 nd in Singapore. The title of Dr. Mohammed's talk will be: "Array-based Diagnostics: A Paradigm Shift in the Diagnosis of Cancers." Dr. Mohammed will be presenting data from over 1000 cancer cases analyzed by CombiMatrix's portfolio of cancer-focused tests.

Dr. Amit Kumar, President and CEO of CombiMatrix, stated, "I am delighted that Dr. Mohammed has been invited to present our diagnostics technology, tests, and real-patient data on a key industry stage. More importantly, to be chosen as one of only four keynote speeches from over 900 oral presentations, representing leading academic and industrial organizations from across the globe, lends incredible validation to the innovativeness and world-class caliber of our tests. We are pleased that our technology and tests continue to garner attention from the scientific and clinical community."

More information about the conference can be found at the following site:


The 3 rd Annual World Cancer Congress is a world stage congress hosted by BIT Life Sciences, between June 22 nd and 25 th, 2010, with over 100 scientific sessions and approximately 1000 speakers from leading academic and industrial institutions from across the world. Oral presentations reflect the latest breakthroughs in the fields of Oncology Research and Drug R & D, Medicine, Medical Devices, Diagnosis, and Public Health Sciences. Additional information about the World Cancer Congress 2010 can be found at:


CombiMatrix Diagnostics offers its newly branded DNA array portfolio of cancer-focused tests to oncologists, hospital-based pathologists and other commercial reference laboratories, through its Irvine, California, CLIA-certified, CAP-accredited laboratory. HemeScan , a high resolution genome-wide analysis of hematologic malignancies such as chronic lymphocytic leukemia, has now been successfully run and resulted in over 1,000 patients. Her2 Pro provides an additional tool in the prognosis of breast cancer, and helps determine a patients' response to specific therapies when other traditional testing methodologies may prove inadequate.  The DNA array technology also provides an overall prognostic portrait of a patient's tumor by measuring levels of genome-wide instability and molecular sub-type associations, and can delineate potential therapeutic targets in various malignancies such as breast, colon and lung cancers.


CombiMatrix Corporation is a diversified biotechnology business that primarily operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Diagnostics ("CMDX").  CMDX operates as a diagnostics reference laboratory that provides genetic and other diagnostics services to physicians, hospitals and clinics.

Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials in the United Kingdom.

Additional information about CombiMatrix Corporation is available at or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at or by calling 1-800-710-0624.

Additional information about CombiMatrix Corporation is available at or by calling 1-800-985-CBMX (2269). Additional information about CombiMatrix Diagnostics is available at or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our periodic and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
CONTACT:  CombiMatrix Corporation          Investor Relations Contact:          Amit Kumar, Ph.D., President & CEO          (425) 493-2000          Fax (425) 493-2010

CombiMatrix Corporation